Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.22 Consensus PT from Brokerages
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among brokers […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among brokers […]
